和邦生物
(603077)
| 流通市值：181.04亿 | | | 总市值：181.04亿 |
| 流通股本：88.31亿 | | | 总股本：88.31亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,784,817,903.44 | 3,064,127,693.33 | 3,882,595,407.22 | 3,744,725,249.02 |
| 应收票据及应收账款 | 1,264,993,483.81 | 977,589,444.12 | 1,309,744,243.56 | 986,023,088.98 |
| 应收账款 | 1,264,993,483.81 | 977,589,444.12 | 1,309,744,243.56 | 986,023,088.98 |
| 应收款项融资 | 1,303,222,105.98 | 1,050,953,392.62 | 726,762,973.57 | 746,669,948.86 |
| 预付款项 | 235,603,353.58 | 190,934,706.93 | 319,710,440.55 | 178,965,754.72 |
| 其他应收款合计 | 36,983,502.85 | 34,354,614 | 35,917,617.61 | 150,048,234.99 |
| 应收股利 | - | - | - | 117,600,000 |
| 存货 | 5,012,592,849.42 | 4,403,120,746.76 | 3,995,865,742.16 | 3,420,594,447.65 |
| 合同资产 | 10,667,890.58 | 20,613,115.06 | 5,123,678.32 | 4,551,194.69 |
| 其他流动资产 | 159,233,400.64 | 112,932,579.22 | 73,814,508.5 | 86,642,372.04 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 10,808,114,490.3 | 9,854,626,292.04 | 10,349,534,611.49 | 9,318,220,290.95 |
| 非流动资产: | | | | |
| 长期股权投资 | - | - | 128,796,157.7 | 123,386,329.81 |
| 其他权益工具投资 | 245,017,889.59 | 207,991,441.31 | 81,736,239.18 | 19,868,208.4 |
| 其他非流动金融资产 | 459,278,185.83 | 459,278,185.83 | 459,278,185.83 | 459,278,185.83 |
| 固定资产 | 8,265,638,025.09 | 8,471,194,783.73 | 7,941,358,947.55 | 8,138,545,778.16 |
| 在建工程 | 1,492,531,183.12 | 1,173,669,134.85 | 1,636,795,997.97 | 1,380,802,488.62 |
| 使用权资产 | 36,282,922.37 | 38,885,540.21 | 17,376,150.15 | 19,647,372.98 |
| 无形资产 | 2,192,394,385.93 | 2,200,383,425.73 | 2,171,640,516.31 | 2,178,747,573.78 |
| 开发支出 | 116,490,024.44 | 100,604,041.73 | 79,728,355.24 | 64,884,690.03 |
| 商誉 | 1,838,405,543.83 | 1,838,405,543.83 | 1,838,405,543.83 | 1,838,405,543.83 |
| 长期待摊费用 | 4,549,416.62 | 4,853,711.84 | 5,158,007.06 | 5,462,302.28 |
| 递延所得税资产 | 53,438,578.32 | 50,383,914.22 | 47,278,542.82 | 45,842,906.64 |
| 其他非流动资产 | 126,873,930.09 | 142,158,107.53 | 103,872,736.24 | 121,336,819.74 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 14,830,900,085.23 | 14,687,807,830.81 | 14,511,425,379.88 | 14,396,208,200.1 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 25,639,014,575.53 | 24,542,434,122.85 | 24,860,959,991.37 | 23,714,428,491.05 |
| 流动负债: | | | | |
| 短期借款 | 1,993,053,690.47 | 1,167,634,821.39 | 1,140,907,735.94 | 893,856,032.76 |
| 应付票据及应付账款 | 2,408,373,420.15 | 1,877,498,599.01 | 1,965,138,759.91 | 1,880,303,449.27 |
| 其中：应付票据 | 672,485,826.42 | 333,499,537.76 | 405,146,745.07 | 321,793,073.49 |
| 应付账款 | 1,735,887,593.73 | 1,543,999,061.25 | 1,559,992,014.84 | 1,558,510,375.78 |
| 合同负债 | 241,209,337.02 | 95,322,709.43 | 142,464,373.93 | 74,447,563.73 |
| 应付职工薪酬 | 61,611,567.57 | 93,965,298.94 | 33,688,178.86 | 52,753,386.24 |
| 应交税费 | 34,378,377.8 | 64,323,313.36 | 117,446,381.6 | 54,957,654.28 |
| 其他应付款合计 | 15,208,517.77 | 15,065,983.82 | 10,858,442.8 | 15,469,921.16 |
| 一年内到期的非流动负债 | 315,547,883.44 | 346,435,627.74 | 143,736,709.07 | 121,849,010.73 |
| 其他流动负债 | 20,935,753.92 | 9,695,496.97 | 14,642,791.71 | 7,718,841.21 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 5,090,318,548.14 | 3,669,941,850.66 | 3,568,883,373.82 | 3,101,355,859.38 |
| 非流动负债: | | | | |
| 长期借款 | 650,251,532.12 | 431,166,233.69 | 667,010,577.38 | 380,396,796.4 |
| 租赁负债 | 23,585,061.41 | 24,944,196.01 | 14,102,544.94 | 18,549,022.04 |
| 递延收益 | 74,041,319.82 | 75,247,653.83 | 77,541,424.86 | 79,492,350.23 |
| 递延所得税负债 | 126,430,783.6 | 122,751,967.37 | 109,057,897.34 | 103,331,331.98 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 874,308,696.95 | 654,110,050.9 | 867,712,444.52 | 581,769,500.65 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 5,964,627,245.09 | 4,324,051,901.56 | 4,436,595,818.34 | 3,683,125,360.03 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 8,831,250,228 | 8,831,250,228 | 8,831,250,228 | 8,831,250,228 |
| 资本公积 | 1,124,527,583.61 | 1,124,527,583.61 | 1,124,527,583.61 | 1,124,527,583.61 |
| 减:库存股 | 1,225,552,269.64 | 650,369,774.03 | 150,000,004.48 | 150,000,004.48 |
| 其他综合收益 | 52,990,236.57 | 51,678,261.78 | 16,861,166.87 | 30,094,575.91 |
| 专项储备 | 17,282,508.09 | 14,726,704.82 | 16,711,698.14 | 20,447,769.28 |
| 盈余公积 | 589,816,235.79 | 589,816,235.79 | 488,124,338.77 | 488,124,338.77 |
| 未分配利润 | 9,643,505,809.4 | 9,613,713,245.31 | 9,451,205,613.43 | 9,048,692,972.75 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 19,033,820,331.82 | 19,575,342,485.28 | 19,778,680,624.34 | 19,393,137,463.84 |
| 少数股东权益 | 640,566,998.62 | 643,039,736.01 | 645,683,548.69 | 638,165,667.18 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 19,674,387,330.44 | 20,218,382,221.29 | 20,424,364,173.03 | 20,031,303,131.02 |
| 负债和股东权益合计 | 25,639,014,575.53 | 24,542,434,122.85 | 24,860,959,991.37 | 23,714,428,491.05 |
| 公告日期 | 2024-04-20 | 2024-04-20 | 2023-10-21 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |